CYP3A5
HGNC ↗3 article(s) in the watch · Pharmacogenomics
CYP3A5 influences the metabolism of tacrolimus, a narrow-therapeutic-index immunosuppressant. Expresser/non-expresser status (the *3 allele) determines the starting dose required to reach target concentrations (CPIC guidelines).
Drugs involved: tacrolimus
Recommendation: CPIC level A
Curated publications
Preemptive Pharmacogenetics in Renal Transplantation: A Real-World Assessment of Pharmacogenetic Actionability
Renal transplantation — preemptive pharmacogenetics
Integrating pharmacogenetic and clinical factors to predict the C0/D/W-based tacrolimus phenotype in kidney transplantation
Tacrolimus — pharmacogenetic prediction of pharmacokinetic phenotype (C0/D/W) in kidney transplantation by integrating CYP3A4/CYP3A5 variants and clinical factors
Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.
Tacrolimus PK variability in pediatric renal transplantation